Schizophrenia Market Size Outlook and Demand Growth Across 2026–2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Schizophrenia Market From 2026 To 2030?

The market size for schizophrenia has shown steady growth recently. Forecasts indicate the market will increase from $6.06 billion in 2025 to $6.35 billion by 2026, achieving a compound annual growth rate (CAGR) of 4.9%. This historical growth is attributable to several factors, including the rising prevalence of schizophrenia, the expansion of psychiatric hospitals and clinics, the availability of both first- and second-generation antipsychotics, increased healthcare spending in developed markets, and advancements in diagnostic criteria and clinical guidelines.

The schizophrenia market is projected to experience substantial expansion in the coming years. This market is set to reach a valuation of $8.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This anticipated growth is attributable to several factors, including a robust pipeline of novel antipsychotic molecules, an increase in long-acting injectable formulations, escalating government efforts in mental health initiatives, improved treatment accessibility in emerging markets, and the incorporation of digital monitoring and adherence tools. Key trends for this period encompass a greater reliance on long-acting injectable antipsychotics, a move towards second- and third-generation antipsychotic drugs, a heightened emphasis on early diagnosis and intervention programs, an expansion of community-based and outpatient treatment models, and the increased uptake of combination therapy and adjunct treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12869&type=smp

What Key Drivers Are Influencing The Growth Of The Schizophrenia Market?

The schizophrenia market is projected to experience growth driven by the increasing demand for anxiety treatment. Anxiety treatment involves various therapeutic methods and interventions aimed at assisting individuals who suffer from excessive and debilitating anxiety symptoms to manage and alleviate their condition. This treatment proves beneficial for individuals with schizophrenia by addressing comorbid anxiety symptoms that often manifest alongside schizophrenia, and it can also help to lessen the severity of psychotic symptoms such as hallucinations and delusions. For example, a report from May 2024 by the American Psychiatric Association, a US-based professional organization of psychologists, revealed that in 2024, 43% of adults reported feeling more anxious, an increase from 37% in 2023 and 32% in 2022, demonstrating a consistent upward trend in anxiety levels. Thus, the escalating demand for anxiety treatment is contributing to the expansion of the schizophrenia market.

Which Segments Are Included In The Analysis Of The Schizophrenia Market?

The schizophrenia market covered in this report is segmented –

1) By Type: Catatonic Schizophrenia, Paranoid Schizophrenia, Undifferentiated Schizophrenia, Hebephrenic Schizophrenia, Residual Schizophrenia, Other Types

2) By Treatment: First-Generation Antipsychotics, Second-Generation Antipsychotics, Third-Generation Antipsychotics, Psychotherapies, Other Treatments

3) By Route of Administration: Oral, Injectables

Subsegments:

1) By Catatonic Schizophrenia: Waxy Flexibility, Stupor, Agitation, Catatonic Excitement

2) By Paranoid Schizophrenia: Delusions Of Persecution, Auditory Hallucinations, Paranoid Ideation

3) By Undifferentiated Schizophrenia: Symptoms Not Specific To Other Types, Mixed Symptoms Of Schizophrenia

4) By Hebephrenic Schizophrenia (Disorganized Schizophrenia): Disorganized Behavior, Disorganized Speech, Emotional Flatness

5) By Residual Schizophrenia: History Of Schizophrenia With Low-Level Symptoms, Social Withdrawal, Mild Hallucinations Or Delusions

6) By Other Types: Schizoaffective Disorder, Brief Psychotic Disorder, Delusional Disorder

Which Trends Are Influencing The Schizophrenia Market?

Leading firms within the schizophrenia market are prioritizing technological innovations, particularly atypical oral antipsychotics that boast enhanced safety and effectiveness, to address the growing demand spurred by the necessity for superior symptom management, broader treatment alternatives for young people, and better patient acceptance. An example is the launch of Rxulti (brexpiprazole) in March 2025, a joint effort by Japan’s Otsuka Pharmaceutical Europe Ltd. and Denmark’s H. Lundbeck A/S, targeting schizophrenia in adolescents who are 13 years and older. This medication, Rxulti, is an atypical oral antipsychotic administered once daily, functioning to modulate serotonin and dopamine systems through its role as a partial agonist at serotonergic 5-HT1A and dopaminergic D2 receptors, coupled with antagonist effects at serotonergic 5-HT2A and noradrenergic a1B/2C receptors. Such a varied receptor binding profile provides a balanced strategy for managing both positive and negative symptoms, accompanied by a good safety record, thereby enhancing treatment compliance and patient results over conventional antipsychotics. The European Commission granted approval following a stringent 6-week randomized clinical trial, which confirmed substantial symptom reduction and excellent tolerability among adolescent patients.

Which Key Industry Participants Are Active In The Schizophrenia Market?

Major companies operating in the schizophrenia market are Pfizer Inc, Johnson And Johnson Services Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Otsuka Holdings Co Ltd, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, Sumitomo Dainippon Pharma Co Ltd, Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck AS, Neurocrine Biosciences Inc, Torrent Pharmaceutical Ltd, Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc, Intra Cellular Therapies Inc, Axsome Therapeutics Inc, Karuna Therapeutics Inc, Minerva Neurosciences Inc

Read the full schizophrenia market report here:

https://www.thebusinessresearchcompany.com/report/schizophrenia-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Schizophrenia Market?

North America was the largest region in the schizophrenia market in 2025. The regions covered in the schizophrenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Schizophrenia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12869&type=smp

Browse Through More Reports Similar to the Global Schizophrenia Market 2026, By The Business Research Company

Antipsychotic Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

Mental Health Global Market Report

https://www.thebusinessresearchcompany.com/report/mental-health-global-market-report

Psychedelic Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/psychedelic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795